News Release

NorthShore neurosurgeon first in Illinois to offer new targeted therapy for brain tumors

Business Announcement

NorthShore University HealthSystem

Julian Bailes, MD, Is Shown during the First GammaTile Surgery in Illinois

image: Dr. Julian Bailes, MD, is the first neurosurgeon in the state of Illinois to offer an advanced targeted radiation therapy designed to delay tumor regrowth for patients with aggressive brain tumors. view more 

Credit: GT Medical, Inc.

NorthShore University HealthSystem (NorthShore) neurosurgeon, Julian Bailes, MD, is the first in Illinois to begin offering GammaTile® Therapy, a new approach to treating malignant brain tumors. The FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) is designed to delay tumor regrowth for patients with high grade gliomas, meningiomas and brain metastases. The first patient in the state was treated by Dr. Bailes who is chairman of the department of neurosurgery and co-director of the NorthShore Neurological Institute. Neuro-oncologist Ryan Merrell, MD, will also be participating in this new surgical therapy at NorthShore.

Aggressive brain tumors tend to be resistant to current treatments and have a high likelihood of recurrence. Smaller than a postage stamp (2cm x 2cm), the GammaTile is a 3D-collagen tile embedded with Cesium-131 radiation that can be placed at the tumor site after the tumor is surgically removed. It immediately begins to target residual tumor cells with radiation while limiting the impact on healthy brain tissue. It adds just five to ten minutes to surgery time and is absorbed in the body within two months; therefore, eliminating the need to be surgically removed.

"We are excited to offer this new treatment that protects healthy brain tissue while providing immediate, targeted therapy directly to the area that's most at risk for recurrence," said Dr. Bailes. "Most patients report fewer side effects and better quality of life since this eliminates the wait time and multiple visits typically associated with standard radiation treatment after the removal of a tumor."

GammaTile Therapy is the only radiation therapy specifically designed for use in the brain and offers advantages for patients undergoing surgery for brain tumors. GammaTile begins targeting residual tumor cells immediately at the time of tumor removal surgery, rather than waiting several weeks for surgical wound healing before beginning treatment. GammaTile protects healthy brain tissue while delivering a targeted dose to any remaining tumor cells. The unique design also limits side effects typically associated with radiation therapy, including hair loss. Additionally, the burden of radiation treatment is reduced for patients treated with GammaTile Therapy. These patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy.

A male patient in his thirties was the first patient in Illinois to receive this treatment. He had brain surgery and standard chemotherapy and radiation last April. Dr. Bailes says GammaTile Therapy shows great promise for prolonging survival and improving quality of life for this patient and others.

Research has shown that patients who received surgery plus GammaTile Therapy had approximately two times improvement in median time to tumor recurrence compared to their most recent prior same site treatment - 19.9 months (a 9.7 month improvement across all tumor types in the clinical study). Additional data supporting the efficacy and safety profile of the therapy for patients with recurrent, previously treated meningioma's was published in the Journal of Neurosurgery (JNS), the official journal of the American Association of Neurological Surgeons.

"We are honored to be working with the brain tumor specialists at NorthShore to deploy GammaTile Therapy for the purpose of improving the lives of patients with brain tumors," said Matt Likens, president and CEO of GT MedTech. "We are excited to begin expanding the availability of GammaTile Therapy to other leading brain tumor treatment centers across the U.S."


About NorthShore University HealthSystem

NorthShore University HealthSystem (NorthShore) is an integrated healthcare delivery system consistently ranked a Top 15 Major Teaching Hospital in the U.S. Headquartered in Evanston, Illinois, NorthShore comprises five hospitals, 140 care sites and 2,300 physicians, serving over 635,000 patients. The organization supports academics and research as the principal teaching affiliate for the University of Chicago Pritzker School of Medicine. Recognized for nursing excellence, NorthShore is a Magnet designated organization--the first system in Illinois to receive this prestigious honor. The system also includes the NorthShore Research Institute, NorthShore Foundation and NorthShore Home & Hospice Services. As a not-for-profit organization, NorthShore provides more than $211 million in charitable care and services to the communities it serves, while philanthropic support from individuals and organizations enhances clinical care, research and education programs.

About GT Medical Technologies, Inc.

Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors in July 2018, and 510(k) regulatory clearance for the treatment of newly diagnosed malignant brain tumors in January 2020. GammaTile Therapy has an established CMS code for Medicare reimbursement. Extensive clinical expertise informed the design of GammaTile Therapy, and deep medical device experience guides the company. The company is headquartered in Tempe, Arizona. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.